Pristiqs: Withdrawal of the marketing authorisation application
On 10 March 2008, Wyeth Europe Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Pristiqs, for the treatment of vasomotor symptoms (hot flushes) associated with the menopause.
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Pristiqs (PDF/378.77 KB)Adopted
First published: 27/06/2008
Last updated: 27/06/2008
Wyeth Europa Ltd withdraws its marketing authorisation application for Pristiqs (desvenlafaxine) (PDF/18.47 KB)
First published: 12/03/2008
Last updated: 12/03/2008
Withdrawal letter : Pristiqs (PDF/60.6 KB)
First published: 10/03/2008
Last updated: 10/03/2008
Questions and answers on the withdrawal of the marketing application for Pristiqs (PDF/38.92 KB)
First published: 04/04/2008
Last updated: 04/04/2008
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').